ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma
The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumor shrinkage correlates with improved survival outcomes,” Hutson said. “We now have compelling evidence that reducing overall tumor burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The new findings demonstrate that patients with greater reductions in total tumor size at disease progression had significantly longer median survival rates. Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasize the importance of aggressive tumor reduction in the fight against renal cell carcinoma,” Hutson added. “The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
About Texas Tech University Health Sciences Center
TTUHSC is a medical education, research and patient care leader dedicated to improving health outcomes across Texas and beyond.
About UMC Health System
UMC Health System is a nationally recognized academic medical center committed to delivering advanced patient care, innovative research and comprehensive cancer treatment.
Related Stories
TTUHSC Among National Academy of Inventors Top 100
For the fourth consecutive year, the National Academy of Inventors (NAI) ranked the Texas Tech University System among the Top 100 U.S. Universities Granted Utility Patents for 2025.
National Academy of Inventors Names TTUHSC Faculty Senior Members
The National Academy of Inventors (NAI) has designated two current and one former TTUHSC faculty researchers as Senior Members.
TTUHSC Cancer Researcher Honored by National Academy of Inventors
C. Patrick Reynolds, M.D., Ph.D., director of the School of Medicine Pediatric Cancer Research Center at TTUHSC, has dedicated his life as a researcher to developing treatments for childhood cancers.
Recent Stories
Future Physicians Find Their Match
March represents springtime, new beginnings and time for Match Day for fourth-year medical students nationwide. TTUHSC School of Medicine students participated in Match Day March 20.
TTUHSC Free Breast Examination Program Expands to Concho Valley
Women in San Angelo and rural communities in the region now have close-to-home access to early breast examination technology at no cost.
TTUHSC Jerry H. Hodge School of Pharmacy Students Celebrate Residency Assignments on Match Day
Fourth-year TTUHSC Jerry H. Hodge School of Pharmacy students interested in completing a residency after they graduate in May have learned where they will spend the next stage of their training during Pharmacy Residency Match Day.